149 related articles for article (PubMed ID: 30230539)
1. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
[TBL] [Abstract][Full Text] [Related]
2. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
[TBL] [Abstract][Full Text] [Related]
3. Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts.
Bassig BA; Shu XO; Koh WP; Gao YT; Purdue MP; Butler LM; Adams-Haduch J; Xiang YB; Kemp TJ; Wang R; Pinto LA; Zheng T; Ji BT; Hosgood HD; Hu W; Yang G; Zhang H; Chow WH; Kim C; Seow WJ; Zheng W; Yuan JM; Lan Q; Rothman N
Int J Cancer; 2015 Dec; 137(11):2688-95. PubMed ID: 26095604
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
Purdue MP; Lan Q; Martinez-Maza O; Oken MM; Hocking W; Huang WY; Baris D; Conde B; Rothman N
Blood; 2009 Sep; 114(13):2730-2. PubMed ID: 19638620
[TBL] [Abstract][Full Text] [Related]
5. Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.
Rhee J; Birmann BM; De Roos AJ; Epstein MM; Martinez-Maza O; Breen EC; Magpantay LI; Levin LI; Visvanathan K; Hosgood HD; Rohan TE; Smoller SW; Bassig BA; Qi L; Shu XO; Koh WP; Zheng W; Yuan JM; Weinstein SJ; Albanes D; Lan Q; Rothman N; Purdue MP
Int J Cancer; 2023 Mar; 152(5):865-878. PubMed ID: 36151863
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma.
Widney D; Gundapp G; Said JW; van der Meijden M; Bonavida B; Demidem A; Trevisan C; Taylor J; Detels R; Martínez-Maza O
Clin Immunol; 1999 Nov; 93(2):114-23. PubMed ID: 10527687
[TBL] [Abstract][Full Text] [Related]
7. Occupational exposure to trichloroethylene is associated with a decline in lymphocyte subsets and soluble CD27 and CD30 markers.
Lan Q; Zhang L; Tang X; Shen M; Smith MT; Qiu C; Ge Y; Ji Z; Xiong J; He J; Reiss B; Hao Z; Liu S; Xie Y; Guo W; Purdue MP; Galvan N; Xin KX; Hu W; Beane Freeman LE; Blair AE; Li L; Rothman N; Vermeulen R; Huang H
Carcinogenesis; 2010 Sep; 31(9):1592-6. PubMed ID: 20530238
[TBL] [Abstract][Full Text] [Related]
8. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.
Purdue MP; Lan Q; Bagni R; Hocking WG; Baris D; Reding DJ; Rothman N
Cancer Res; 2011 Jul; 71(14):4898-907. PubMed ID: 21632552
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
[TBL] [Abstract][Full Text] [Related]
10. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies.
Makgoeng SB; Bolanos RS; Jeon CY; Weiss RE; Arah OA; Breen EC; Martínez-Maza O; Hussain SK
JNCI Cancer Spectr; 2018 Dec; 2(4):pky082. PubMed ID: 30873511
[TBL] [Abstract][Full Text] [Related]
11. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.
Hosnijeh FS; Portengen L; Späth F; Bergdahl IA; Melin B; Mattiello A; Masala G; Sacerdote C; Naccarati A; Krogh V; Tumino R; Chadeau-Hyam M; Vineis P; Vermeulen R
Int J Cancer; 2016 May; 138(10):2357-67. PubMed ID: 26684261
[TBL] [Abstract][Full Text] [Related]
12. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
Levin LI; Breen EC; Birmann BM; Batista JL; Magpantay LI; Li Y; Ambinder RF; Mueller NE; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1114-1123. PubMed ID: 28341757
[No Abstract] [Full Text] [Related]
13. Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.
Purdue MP; Lan Q; Kemp TJ; Hildesheim A; Weinstein SJ; Hofmann JN; Virtamo J; Albanes D; Pinto LA; Rothman N
Leukemia; 2015 Jun; 29(6):1429-31. PubMed ID: 25567136
[No Abstract] [Full Text] [Related]
14. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies.
Kersten MJ; Evers LM; Dellemijn PL; van den Berg H; Portegies P; Hintzen RQ; van Lier RA; von dem Borne AE; van Oers RH
Blood; 1996 Mar; 87(5):1985-9. PubMed ID: 8634448
[TBL] [Abstract][Full Text] [Related]
15. Levels of serum and cerebrospinal fluid soluble CD27 in the diagnosis of leptomeningeal involvement of hematolymphoid malignancies.
Kara IO; Sahin B; Gunesacar R
Adv Ther; 2007; 24(4):741-7. PubMed ID: 17901023
[TBL] [Abstract][Full Text] [Related]
16. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.
De Roos AJ; Mirick DK; Edlefsen KL; LaCroix AZ; Kopecky KJ; Madeleine MM; Magpantay L; Martínez-Maza O
Cancer Res; 2012 Sep; 72(18):4733-43. PubMed ID: 22846913
[TBL] [Abstract][Full Text] [Related]
17. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.
Edlefsen KL; Martínez-Maza O; Madeleine MM; Magpantay L; Mirick DK; Kopecky KJ; LaCroix AZ; De Roos AJ
Int J Cancer; 2014 Aug; 135(4):913-22. PubMed ID: 24488825
[TBL] [Abstract][Full Text] [Related]
18. Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.
Hussain SK; Hessol NA; Levine AM; Breen EC; Anastos K; Cohen M; D'Souza G; Gustafson DR; Silver S; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2084-93. PubMed ID: 24045923
[TBL] [Abstract][Full Text] [Related]
19. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.
Breen EC; Hussain SK; Magpantay L; Jacobson LP; Detels R; Rabkin CS; Kaslow RA; Variakojis D; Bream JH; Rinaldo CR; Ambinder RF; Martinez-Maza O
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1303-14. PubMed ID: 21527584
[TBL] [Abstract][Full Text] [Related]
20. Soluble cytokine receptor CD30 in atopic disorders: a case-control study.
Latza U; Davis S; Wilhelm D; McKnight B; Seyfarth M; Stein H
Clin Exp Allergy; 1999 Jan; 29(1):97-104. PubMed ID: 10051708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
